Impact of tocilizumab on clinical outcomes in severe covid-19 patients and risk of secondary infection: A case-control study

Year 2021, Volume: 34 Issue: 2, 112 - 119, 31.05.2021

Buket Erturk Sengel Serra Ozel Fethi Gul Can Ilgın Elif Tukenmez Tıgen Luftiye Nilsun Altunal Feyyaz Kabadayı Uluhan Sılı Mehtap Aydın Zekaver Odabası Ismail Cınel Volkan Korten

https://doi.org/10.5472/marumj.942700

Abstract

Objective: This study aimed to identify the effect of tocilizumab (TCZ) on clinical outcomes in severe COVID-19 patients.
Material and Methods: We included hospitalized COVID-19 patients with an initial WHO scale ≥4. We matched the patients with
baseline characteristics by using propensity scores. Then, we selected patients with C-reactive protein levels above 30 and showing
an upward trend. We assessed the effect of TCZ in patients on clinical outcomes by using Mann – Whitney U and Chi-square tests.
Results: Of 200 patients who had an initial WHO scale ≥ 4, 42 (21%) were given TCZ in addition to standard of care (SOC). Twentyfive
patients (50%) needed mechanical ventilation (MV) in the TCZ group, compared with 35 (21%) of 158 patients with SOC
(p<0.01). Nineteen (45%) and 37 (23%) patients died in 30 days in these groups, respectively (p <0.01). The secondary infection rate
was significantly higher in the TCZ group (p=0.004). However, no difference was observed in all these parameters in the propensity
score-matched cohort (14 patients in TCZ and 14 in the SOC group) (p=0.45, 0.45, 1.0 respectively).
Conclusions: Tocilizumab does not provide a beneficial effect on MV requirement and mortality in severe COVID-19, and it does not
increase the risk of secondary bacterial infection.

Keywords

COVID-19, IL-6, SARS-CoV-2, Tocilizumab

References

• World Health Organization. Coronavirus Disease 2019 (COVID-19) – Situation Report. Available at: <https:// www.who.int/publications/m/item/weekly-epidemiologicalupdate—- 29-december-2020>. Accessed: 05.01.2021
• Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020;368:473-4. doi: 10.1126/science. abb8925
• Hirano T, Murakami M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020;52:731-3. doi: 10.1016/j.immuni.2020.04.003
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62. doi:https://doi.org/10.1016/S0140-6736(20)30566-3
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4. doi:https://doi.org/10.1016/S0140- 6736(20)30628-0
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. doi:https://doi.org/10.1016/S0140- 6736(20)30183-5
• Zhang C, Wu Z, Li JW, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020;55:105954. doi: 10.1016/j.ijantimicag.2020.105954
• Navarro G, Taroumian S, Barroso N, et al. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum 2014;43:458-69. doi: 10.1016/j.semarthrit.2013.08.001
• Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum2005;52:818-25. doi: 10.1002/art.20944
• Navarro-Millan I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 2012;34:788- 802 e3. doi: 10.1016/j.clinthera.2012.02.014
• Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 2020;92:814-8. doi: 10.1002/jmv.25801
• Sciascia S, Apra F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020;38:529-32.
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117:10970-5. doi: 10.1073/pnas.200.561.5117
• Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect 2020;50:397-400. doi: 10.1016/j.medmal.2020.05.001
• Rossotti R, Travi G, Ughi N, et al. Safety and efficacy of antiil6- receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. J Infect 2020;81:e11-e7. doi: 10.1016/j.jinf.2020.07.008
• Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol2020;2:e474-e84. doi: 10.1016/S2665- 9913(20)30173-9
• Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med 2020;76:31-5. doi: 10.1016/j.ejim.2020.05.009
• Hill JA, Menon MP, Dhanireddy S, et al. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. J Med Virol 2020. doi: 10.1002/jmv.26674
• Patel K, Gooley TA, Bailey N, et al. Use of the IL-6R antagonist tocilizumab in hospitalized COVID-19 patients. J Intern Med 2020. doi: 10.1111/joim.13163
• Somers EC, Eschenauer GA, Troost JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020;ciaa954. doi: 10.1093/cid/ciaa954
• World Health Organisation (WHO). COVID-19 Therapeutic Trial Synopsis. Available at: <https://www.who.int/ publications/i/item/covid-19-therapeutic-trial-synopsis>. Accessed: 20.07.2020
• National Institutes of Health (NIH). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Clinical Spectrum of SARS-CoV-2 Infection. Available at: <https://www. covid19treatmentguidelines.nih.gov/overview/clinicalspectrum/>. Accessed: 27.07.2020
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424. doi: 10.1080/00273.171.2011.568786
• Henderson AR. Testing experimental data for univariate normality. Clin Chim Acta 2006;366:112-29. doi: 10.1016/j. cca.2005.11.007
• Huang I, Pranata R, Lim MA, et al. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis 2020;14:175.346.6620937175. doi: 10.1177/175.346.6620937175
• Zhou B SJ, Wang Y, Ma X. Utility of ferritin, procalcitonin, and C-reactive protein in severe patients with 2019 novel coronavirus disease. Research Square 2020. doi:10.21203/ rs.3.rs-18079/v1
• Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21:904-13. doi: 10.1016/ S1470-2045(20)30310-7
• Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care 2020;8:36. doi:10.1186/ s40560.020.00453-4
• Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med 2020;383:2333-44. doi: 10.1056/NEJMoa2028836
• Rossi B, Nguyen LS, Zimmermann P, et al. Effect of tocilizumab in hospitalized patients with severe covid-19 pneumonia: A case-control cohort study. Pharmaceuticals (Basel) 2020;13 :317. doi :10.3390/ph13100317
• Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 2020;76:43-9. doi: 10.1016/j.ejim.2020.05.021
• Rojas-Marte G, Khalid M, Mukhtar O, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. QJM 2020;113:546-50. doi: 10.1093/qjmed/hcaa206
• Allenbach Y, Saadoun D, Maalouf G, et al. Development of multivariable prediction model of intensive care unit transfer or death: A French prospective cohort study of COVID-19 patients. PLoS ONE 2020;15:e0240711. doi: doi.org/10.1371/ journal.pone.0240711
• RECOVERY Collaborative Group HP, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384:693-704. doi: 10.1056/ NEJMoa2021436
• Nelson BC, Laracy J, Shoucri S, et al. Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19. Clin Infect Dis 2021;72:e367-372.. doi: 10.1093/cid/ciaa1163
• Fernandez-Ruiz M, Lopez-Medrano F, Perez-Jacoiste Asin MA, et al. , . Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study. J Med Virol 2021;93:831-42 doi. 10.1002/jmv.26308
• Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020;26:1622-9. doi:10.1016/j.cmi.2020.07.016